Valuation : Orexo AB

Market Cap 53Cr 5.53Cr 4.76Cr 4.47Cr 4.09Cr 7.65Cr 521.79Cr 7.67Cr 21Cr 267.71Cr 21Cr 20Cr 862.44Cr P/E 2026 *
-1.45x
P/E 2027 * -2.08x
Enterprise Value 42Cr 4.43Cr 3.81Cr 3.59Cr 3.28Cr 6.13Cr 418.16Cr 6.14Cr 16Cr 214.55Cr 17Cr 16Cr 691.17Cr EV / Sales 2026 *
22.3x
EV / Sales 2027 * 14.3x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-2.38%
1 week-6.50%
Current month-6.50%
3 months-22.41%
6 months-41.28%
Current year-51.23%
1 week 14.64
Extreme 14.64
16.6
1 month 12.9
Extreme 12.9
16.6
Current year 12.9
Extreme 12.9
36
1 year 12.9
Extreme 12.9
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/25 Buy

Chief Executive Officer

6 0.0000%
04/09/25 Free

Chief Executive Officer

1,393 0.0040%
03/09/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-6.50%-40.81%-16.78% 5.53Cr
-1.32%+1.33%+77.46%+41.17% 37TCr
-0.75%-3.06%+21.45%-19.53% 6.86TCr
-0.51%+4.59%+47.06%+168.63% 1.25TCr
-0.56%-9.06%-8.11%-8.78% 806.4Cr
+0.23%-1.59%-20.70%+6.13% 503.58Cr
0.00%-4.12%-31.60%+20.55% 450.91Cr
-0.35%-3.11%-33.77%+1.20% 306.95Cr
-1.00%-0.46%-5.37%+37.45% 253.03Cr
-0.50%-3.98%-24.35%-16.61% 200.07Cr
Average -0.71%-0.26%-1.87%+21.34% 4.77TCr
Weighted average by Cap. -1.16%+0.48%+63.51%+33.85%

Financials

2026 *2027 *
Net sales 1.9Cr 19.86L 17.09L 16.08L 14.69L 27.48L 19Cr 27.55L 73.73L 9.62Cr 74.58L 72.95L 31Cr 2.7Cr 28.22L 24.29L 22.85L 20.87L 39.05L 27Cr 39.15L 1.05Cr 14Cr 1.06Cr 1.04Cr 44Cr
Net income -38Cr -3.92Cr -3.37Cr -3.17Cr -2.9Cr -5.42Cr -370.09Cr -5.44Cr -15Cr -189.88Cr -15Cr -14Cr -611.7Cr -27Cr -2.83Cr -2.43Cr -2.29Cr -2.09Cr -3.91Cr -266.96Cr -3.92Cr -10Cr -136.97Cr -11Cr -10Cr -441.24Cr
Net Debt -10Cr -1.1Cr -94.44L -88.86L -81.17L -1.52Cr -103.62Cr -1.52Cr -4.07Cr -53Cr -4.12Cr -4.03Cr -171.28Cr -14Cr -1.49Cr -1.29Cr -1.21Cr -1.11Cr -2.07Cr -141.13Cr -2.07Cr -5.55Cr -72Cr -5.61Cr -5.49Cr -233.26Cr
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
07/26/07 SEK 14.68 -3.04% 12,551
04/26/04 SEK 15.14 -1.69% 19,314
03/26/03 SEK 15.40 +1.05% 22,080
02/26/02 SEK 15.24 +1.20% 13,800
01/26/01 SEK 15.06 -4.08% 1,54,190
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!